Stewart R M, Miller S, Gunder M
Acta Derm Venereol. 1983;63(2):97-101.
The effect of anti-Parkinson therapy on the urinary excretion of 5-S-cysteinyldopa (5SCD), a catechol metabolite of dihydroxyphenylalanine (DOPA) and marker for the melanocyte, was studied by means of high performance liquid chromatography. 5SCD was normal in Parkinson patients treated with anticholinergics. DOPA administration increased 5SCD excretion. Carbidopa and DOPA together elevated 5SCD markedly in a dose-dependent manner to values higher than seen in some patients with metastatic malignant melanoma. The effect of anti-Parkinson therapy should be considered when using 5SCD as a tumor marker or when a Parkinson patient has a melanoma.
采用高效液相色谱法研究了抗帕金森病疗法对5-S-半胱氨酰多巴（5SCD）尿排泄的影响，5SCD是二羟基苯丙氨酸（DOPA）的儿茶酚代谢产物，也是黑素细胞的标志物。接受抗胆碱能药物治疗的帕金森病患者5SCD水平正常。给予DOPA会增加5SCD的排泄。卡比多巴和DOPA联合使用能以剂量依赖的方式显著提高5SCD水平，使其高于一些转移性恶性黑色素瘤患者的水平。在将5SCD用作肿瘤标志物时，或者帕金森病患者患有黑色素瘤时，应考虑抗帕金森病疗法的影响。
